

Michael A Barras Bpharm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1487633/publications.pdf>

Version: 2024-02-01

77
papers

1,405
citations

430442

18
h-index

395343

33
g-index

79
all docs

79
docs citations

79
times ranked

2167
citing authors

#	ARTICLE	IF	CITATIONS
1	Recurrent readmissions in medical patients: A prospective study. <i>Journal of Hospital Medicine</i> , 2011, 6, 61-67.	0.7	128
2	The development and evaluation of an oncological palliative care deprescribing guideline: the "OncPal deprescribing guideline". <i>Supportive Care in Cancer</i> , 2015, 23, 71-78.	1.0	112
3	Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. <i>Clinical Biochemist Reviews</i> , 2010, 31, 21-4.	3.3	98
4	Endothelial function and dysfunction: Impact of metformin. , 2018, 192, 150-162.		82
5	Drug dosing in obese adults. <i>Australian Prescriber</i> , 2017, 40, 189-193.	0.5	72
6	Using EMR-enabled computerized decision support systems to reduce prescribing of potentially inappropriate medications: a narrative review. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 559-573.	1.0	71
7	Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches. <i>Supportive Care in Cancer</i> , 2014, 22, 1113-1119.	1.0	64
8	Systematic review of predictive risk models for adverse drug events in hospitalized patients. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 846-864.	1.1	52
9	New oral anticoagulants: appropriateness of prescribing in real-world setting. <i>Internal Medicine Journal</i> , 2016, 46, 812-818.	0.5	51
10	Individualised medicine: why we need Bayesian dosing. <i>Internal Medicine Journal</i> , 2017, 47, 593-600.	0.5	40
11	Current Status of Therapeutic Drug Monitoring in Australia and New Zealand: A Need for Improved Assay Evaluation, Best Practice Guidelines, and Professional Development. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 615-623.	1.0	35
12	Defining and classifying terminology for medication harm: a call for consensus. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 137-145.	0.8	35
13	Individualized Compared With Conventional Dosing of Enoxaparin. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 882-888.	2.3	34
14	Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6698-6702.	1.4	33
15	Reporting a Population Pharmacokineticâ€“Pharmacodynamic Study: A Journalâ€™s Perspective. <i>Clinical Pharmacokinetics</i> , 2014, 53, 111-122.	1.6	30
16	Effects of a pilot multidisciplinary clinic for frequent attending elderly patients on deprescribing. <i>Australian Health Review</i> , 2016, 40, 86.	0.5	26
17	Investigating strategies used by hospital pharmacists to effectively communicate with patients during medication counselling. <i>Health Expectations</i> , 2017, 20, 1121-1132.	1.1	22
18	Teaching people with Parkinsonâ€™s disease about their medication. <i>Nursing Older People</i> , 2005, 17, 14-20.	0.1	21

#	ARTICLE	IF	CITATIONS
19	Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?. <i>Clinical Pharmacokinetics</i> , 2019, 58, 389-399.	1.6	20
20	Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 700-711.	1.1	19
21	A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2017, 25, 607-613.	1.0	19
22	ROS directly activates transforming growth factor β type 1 receptor signalling in human vascular smooth muscle cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129463.	1.1	18
23	Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 520-528.	1.1	17
24	Hospital pharmacists' perceptions of medication counseling: A focus group study. <i>Research in Social and Administrative Pharmacy</i> , 2016, 12, 756-771.	1.5	16
25	How hospital pharmacists prioritise patients at high-risk for medication harm. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 1266-1273.	1.5	16
26	Economic benefits of pharmacy technicians practicing at advanced scope: A systematic review. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1344-1353.	1.5	15
27	Individualized Dosing of Enoxaparin for Subjects With Renal Impairment Is Superior to Conventional Dosing at Achieving Therapeutic Concentrations. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 482-488.	1.0	14
28	Hospital pharmacists' and patients' views about what constitutes effective communication between pharmacists and patients. <i>International Journal of Pharmacy Practice</i> , 2018, 26, 450-457.	0.3	13
29	Interventions designed to improve the safety and quality of therapeutic anticoagulation in an inpatient electronic medical record. <i>International Journal of Medical Informatics</i> , 2020, 135, 104066.	1.6	13
30	Development and validation of the Adverse Inpatient Medication Event model (AIME). <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1512-1524.	1.1	12
31	Routine Plasma Anti-Xa Monitoring is Required for Low-Molecular-Weight Heparins. <i>Clinical Pharmacokinetics</i> , 2010, 49, 567-571.	1.6	10
32	Systematic review of machine learning models for personalised dosing of heparin. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4124-4139.	1.1	10
33	Exploring factors of uneven use of telehealth among outpatient pharmacy clinics during COVID-19: A multi-method study. <i>Research in Social and Administrative Pharmacy</i> , 2022, 18, 3602-3611.	1.5	10
34	Toward a Learning Health Care System: A Systematic Review and Evidence-Based Conceptual Framework for Implementation of Clinical Analytics in a Digital Hospital. <i>Applied Clinical Informatics</i> , 2022, 13, 339-354.	0.8	10
35	Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 387-393.	1.0	9
36	A Narrative Review of Aspirin Resistance in VTE Prophylaxis for Orthopaedic Surgery. <i>Drugs</i> , 2020, 80, 1889-1899.	4.9	9

#	ARTICLE	IF	CITATIONS
37	Platelet Function Assays for the Diagnosis of Aspirin Resistance. <i>Platelets</i> , 2022, 33, 329-338.	1.1	9
38	Abnormal laboratory results: Anti-Xa assays. <i>Australian Prescriber</i> , 2013, 36, 98-101.	0.5	9
39	Facing the challenges of new melanoma-targeted therapies: Treatment of severe fevers associated with dabrafenib/trametinib combination therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 293-295.	0.5	8
40	The type and incidence of adverse drug events in ageing medical inpatients and their effect on length of hospital stay. <i>Journal of Pharmacy Practice and Research</i> , 2017, 47, 347-354.	0.5	8
41	Pharmacists reducing medication risk in medical outpatient clinics: a retrospective study of 18 clinics. <i>Internal Medicine Journal</i> , 2023, 53, 95-103.	0.5	8
42	Scoping Review of Studies Evaluating Frailty and Its Association with Medication Harm. <i>Drugs and Aging</i> , 2022, 39, 333-353.	1.3	7
43	Bayesian Optimisation of Tobramycin Dosing in Paediatric Patients with Cystic Fibrosis. <i>Journal of Pharmacy Practice and Research</i> , 2011, 41, 183-187.	0.5	6
44	Reducing the risk of harm from intravenous potassium: A multi-factorial approach in the haematology setting. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 323-331.	0.5	6
45	Improving Care Transitions in Individuals Frequently Admitted to the Hospital. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 1994-1996.	1.3	6
46	Therapeutic drug monitoring: using Bayesian methods to evaluate hospital practice. <i>Journal of Pharmacy Practice and Research</i> , 2018, 48, 522-529.	0.5	6
47	Systematic review of interventions to improve safety and quality of anticoagulant prescribing for therapeutic indications for hospital inpatients. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1645-1657.	0.8	6
48	Unfractionated heparin dosing in obese patients. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 462-473.	1.0	6
49	Treatment strategies for clozapine-induced hypotension: a systematic review. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532210929.	1.2	6
50	Using Discursis to enhance the qualitative analysis of hospital pharmacist-patient interactions. <i>PLoS ONE</i> , 2018, 13, e0197288.	1.1	5
51	Patient harm from cardiovascular medications. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862110274.	1.0	5
52	An evaluation of pharmacist activity in hospital outpatient clinics. <i>Journal of Pharmacy Practice and Research</i> , 2021, 51, 328-332.	0.5	5
53	Examining hospital pharmacists' goals for medication counseling within the communication accommodation theoretical framework. <i>Research in Social and Administrative Pharmacy</i> , 2016, 12, 747-755.	1.5	4
54	Direct oral anticoagulants: New drugs with practical problems. How can nurses help prevent patient harm?. <i>Australian Journal of Cancer Nursing</i> , 2016, 18, 408-411.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Integrating a pharmacist into the perioperative setting. Australian Health Review, 2020, 44, 563-568.	0.5	4
56	Patients' Understanding of Drug Allergy and Documentationâ€”Is There a Link?. Journal of Pharmacy Practice and Research, 2005, 35, 276-278.	0.5	3
57	Compliance With Enoxaparin Dosing and Monitoring Guidelines and the Impact on Patient Length of Stay. Therapeutic Drug Monitoring, 2016, 38, 59-63.	1.0	3
58	Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis: an Update. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	3
59	A randomised trial of pharmacist-led discharge prescribing in an Australian geriatric evaluation and management service. International Journal of Clinical Pharmacy, 2021, 43, 847-857.	1.0	3
60	Transit Care Hub pharmacist: improving patient flow within the hospital. International Journal of Clinical Pharmacy, 2020, 42, 1319-1325.	1.0	3
61	Benefits, challenges and contributors to the introduction of new hospital-based outpatient clinic pharmacist positions. Exploratory Research in Clinical and Social Pharmacy, 2022, 5, 100119.	0.6	3
62	Inpatient smoking cessation â€” turn to your clinical pharmacist. Australian and New Zealand Journal of Public Health, 2016, 40, 498.	0.8	2
63	Developing Preliminary Steps in a Pharmacist Communication â€” Patient Outcome Pathway. Canadian Journal of Hospital Pharmacy, 2019, 72, .	0.1	2
64	Myalgia in Patients on Highâ€”Dose and Lowâ€”toâ€”Moderate Dose Statin Therapy. Journal of Pharmacy Practice and Research, 2009, 39, 202-206.	0.5	1
65	Comparison of 2 Weight-Based Heparin Dosing Nomograms in Neurology and Vascular Surgical Patients. Therapeutic Drug Monitoring, 2015, 37, 33-39.	1.0	1
66	Reply to Iuga and Genaidy â€” Comment on Falconer <i>et al</i> . (2018) â€” the need for specific adverse drug reaction outcomesâ€”. British Journal of Clinical Pharmacology, 2018, 84, 1857-1857.	1.1	1
67	Conversion of other opioids to methadone: a retrospective comparison of two methods. BMJ Supportive and Palliative Care, 2020, 10, 201-204.	0.8	1
68	Identifying medication harm in hospitalised patients: a bimodal, targeted approach. Therapeutic Advances in Drug Safety, 2020, 11, 204209862097551.	1.0	1
69	Assessing Communication Behaviours of Hospital Pharmacists: How Well Do the Perspectives of Pharmacists, Patients, and an Independent Observer Align?. Journal of Language and Social Psychology, 2020, 39, 626-652.	1.2	1
70	Comment On: â€”Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Studyâ€”. Clinical Drug Investigation, 2020, 40, 287-288.	1.1	1
71	A Randomized Trial of Olanzapine and Palonosetron versus Infused Ondansetron for the Treatment of Chemotherapy Induced Nausea and Vomiting in Patients Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 1910-1910.	0.6	1
72	Medicinal mishap: Dabigatran â€” a new safe drug to replace an old poison?. Australian Prescriber, 2012, 35, 64-65.	0.5	1

#	ARTICLE	IF	CITATIONS
73	Are Patients on Long-term Corticosteroids Receiving Bone Loss Therapy?. Journal of Pharmacy Practice and Research, 2006, 36, 29-31.	0.5	0
74	Pharmacists Investigating Adverse Penicillin Responses—Pilot Study. Journal of Pharmacy Practice and Research, 2007, 37, 200-203.	0.5	0
75	Developing Preliminary Steps in a Pharmacist Communication - Patient Outcome Pathway. Canadian Journal of Hospital Pharmacy, 2019, 72, 271-281.	0.1	0
76	Evaluation of two European risk models for predicting medication harm in an Australian patient cohort. European Journal of Clinical Pharmacology, 2022, 78, 679.	0.8	0
77	Infusion reaction incidence after switching all patients to an infliximab biosimilar in an Australian hospital. Journal of Pharmacy Practice and Research, 0, , .	0.5	0